Allogeneic g-NK cell therapy

Natural killer (NK) cells are innate immune lymphocytes that recognize and destroy abnormal cells—such as virally infected or malignant cells—without requiring prior sensitization to a specific antigen, unlike T cells. They achieve this through a balance of activating and inhibitory receptor signals: when a cell downregulates the surface markers that normally signal 'self' (a phenomenon called missing-self recognition), or displays stress ligands, NK cells are triggered to release cytotoxic granules and pro-inflammatory cytokines. Allogeneic NK cell therapy uses NK cells manufactured from a healthy donor rather than the patient, expanded and processed for infusion into multiple recipients as a standardized, 'off-the-shelf' product. This approach is being explored broadly in oncology, where the goal is to supplement or restore anti-tumor immune surveillance, particularly in cancers that evade T-cell-based approaches or in patients whose own immune cells are depleted or dysfunctional. Because NK cell alloreactivity does not require the same degree of donor-recipient genetic matching that T-cell therapies do, allogeneic sourcing is more feasible for NK cells than for many T-cell products, supporting scalable manufacturing and broader patient access to cellular immunotherapy.